Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.64 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | TEK | Q02763 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29820100 | 0.80 | CYP19A1 (0.69) | CYP19A1CYP11B1CYP11B2ALDH1A1TDP1 | |
| SCHEMBL3107233 | 0.80 | CYP19A1 (0.64) | CYP19A1CYP11B1CYP11B2ALDH1A1TDP1 | |
| SCHEMBL16100647 | 0.80 | CYP19A1 (0.64) | CYP19A1CYP11B1CYP11B2TDP1HTR1A | |
| SCHEMBL29820311 | 0.80 | CYP19A1 (0.64) | CYP19A1CYP11B1CYP11B2L3MBTL1ALDH1A1 | |
| SCHEMBL31286290 | 0.80 | CYP19A1 (0.64) | CYP19A1CYP11B1CYP11B2TDP1HTR1A | |
| SCHEMBL3153071 | 0.79 | CYP19A1 (0.67) | CYP19A1CYP11B1CYP11B2ALDH1A1TDP1 | |
| SCHEMBL155247 | 0.78 | CYP19A1 (1.00) | CYP19A1CYP11B1CYP11B2L3MBTL1 | |
| SCHEMBL1851019 | 0.78 | HTT (0.59) | CYP11B1CYP11B2L3MBTL1ALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL7263772 | 0.77 | CYP19A1 (0.96) | CYP19A1CYP11B1CYP11B2L3MBTL1 | |
| SCHEMBL2163185 | 0.77 | L3MBTL1 (0.50) | CYP19A1CYP11B1CYP11B2L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6864255-B2 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. | 2003-05-08 | — | — | US | disclosed |
| EP-0612731-B1 | Novel guinolone and naphthyridone derivatives | BAYER AG (DE) | 1997-08-20 | — | — | EP | disclosed |
| EP-0612731-A1 | Novel guinolone and naphthyridone derivatives | BAYER AG (DE) | 1994-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | FLT4, FLT1, VEGFA | CYP19A1 215/4885CYP11B1 732/4885CYP11B2 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.